Cover Image
市場調查報告書

Alchemia Limited:產品平台分析

Alchemia Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 192449
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Alchemia Limited:產品平台分析 Alchemia Ltd - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 32 Pages
簡介

本報告提供Alchemia Limited的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Alchemia Limited的基本資料

Alchemia Limited概要

  • 主要資訊
  • 企業資料

Alchemia Limited:R&D概要

  • 主要的治療範圍

Alchemia Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Alchemia Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Alchemia Limited:藥物簡介

  • irinotecan hydrochloride
  • doxorubicin
  • fluorouracil
  • Antibiotic Program
  • bevacizumab
  • carboplatin
  • cetuximab
  • fondaparinux sodium
  • gemcitabine
  • methotrexate
  • Small Molecules to Inhibit Focal Adhesion Kinase for Solid Tumors 28
  • vinorelbine tartrate
  • Small Molecule Targeting Parathyroid Hormone
  • Small Molecule Targeting Gastric Inhibitory Polypeptide
  • Small Molecule Targeting GLP-1 For Diabetes
  • Small Molecule Targeting Nav1.7 For Pain
  • Small Molecule Targeting Opioid Receptor For Pain
  • Small Molecule Targeting VPAC Receptor For COPD
  • VAST Based Drug For Multiple Indications

Alchemia Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alchemia Limited:最近的開發平台趨勢

Alchemia Limited:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • 肥胖症的VAST為基礎藥物
    • ACL-16907

Alchemia Limited:企業發表

Alchemia Limited:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08183CDB

Summary

Global Markets Direct's, 'Alchemia Ltd - Product Pipeline Review - 2016', provides an overview of the Alchemia Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alchemia Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Alchemia Ltd
  • The report provides overview of Alchemia Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alchemia Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alchemia Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Alchemia Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alchemia Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alchemia Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alchemia Ltd Snapshot
    • Alchemia Ltd Overview
    • Key Facts
  • Alchemia Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Alchemia Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alchemia Ltd - Pipeline Products Glance
    • Alchemia Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alchemia Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alchemia Ltd - Drug Profiles
    • HA-5FU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HA-Doxorubicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Target CD44 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Respiratory, Oncology, Cardiovascular, Metabolic Disorders, Infectious Disease and Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Gram-Positive Bacterial Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alchemia Ltd - Pipeline Analysis
    • Alchemia Ltd - Pipeline Products by Target
    • Alchemia Ltd - Pipeline Products by Route of Administration
    • Alchemia Ltd - Pipeline Products by Molecule Type
    • Alchemia Ltd - Pipeline Products by Mechanism of Action
  • Alchemia Ltd - Dormant Projects
  • Alchemia Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ACL-16907
      • VAST Based Drug For Obesity
  • Alchemia Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alchemia Ltd, Key Facts
  • Alchemia Ltd - Pipeline by Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Phase II, 2016
  • Alchemia Ltd - Preclinical, 2016
  • Alchemia Ltd - Discovery, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Route of Administration, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
  • Alchemia Ltd - Dormant Developmental Projects,2016
  • Alchemia Ltd - Discontinued Pipeline Products, 2016
  • Alchemia Ltd, Subsidiaries

List of Figures

  • Alchemia Ltd - Pipeline by Top 10 Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top